Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $647 | In Stock | |
10 mg | $987 | In Stock |
Description | Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM). |
In vitro | Combining lexatumumab with cisplatin can synergistically inhibit cell growth and enhance apoptosis and death[1]. In different melanoma cell lines, lexatumumab (0-10 μg/ml, 72 h) induced varying degrees of cell death[2]. |
In vivo | Lexatumumab ( 10mg / kg, intravenous injection, twice a week ) combined with Dacarbazine can increase the anti-tumor effect in mice [ 2 ]. |
Alias | HGS-ETR 2, ETR2-ST01, DR5 mAB |
Molecular Weight | 143.48 kDa |
Cas No. | 845816-02-6 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.